Joseph Stringer
Stock Analyst at Needham
(1.36)
# 3,107
Out of 4,805 analysts
320
Total ratings
28.37%
Success rate
-10.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Reiterates: Buy | $60 | $24.80 | +141.94% | 17 | Apr 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $6.43 | +242.15% | 22 | Apr 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $320 | $243.27 | +31.54% | 21 | Apr 9, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $4.43 | +532.05% | 50 | Apr 9, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $90 | $30.80 | +192.21% | 17 | Apr 8, 2025 | |
| IONS Ionis Pharmaceuticals | Reiterates: Buy | $60 | $27.77 | +116.06% | 19 | Apr 8, 2025 | |
| INZY Inozyme Pharma | Reiterates: Buy | $15 | $0.91 | +1,555.81% | 18 | Apr 8, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $66 | $60.23 | +9.58% | 23 | Apr 8, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Buy | $35 | $17.47 | +100.34% | 9 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Reiterates: Hold | n/a | $0.49 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $1.42 | +1,026.76% | 18 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.31 | +663.36% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $5.72 | +232.17% | 16 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $105.25 | - | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $482.30 | - | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $26.67 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $60 | $19.61 | +205.97% | 19 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.90 | - | 16 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $14.96 | +147.33% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $8.53 | +111.02% | 2 | Aug 24, 2021 |
Avidity Biosciences
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $24.80
Upside: +141.94%
Stoke Therapeutics
Apr 9, 2025
Reiterates: Buy
Price Target: $22
Current: $6.43
Upside: +242.15%
Alnylam Pharmaceuticals
Apr 9, 2025
Reiterates: Buy
Price Target: $320
Current: $243.27
Upside: +31.54%
Phathom Pharmaceuticals
Apr 9, 2025
Reiterates: Buy
Price Target: $28
Current: $4.43
Upside: +532.05%
Vaxcyte
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $30.80
Upside: +192.21%
Ionis Pharmaceuticals
Apr 8, 2025
Reiterates: Buy
Price Target: $60
Current: $27.77
Upside: +116.06%
Inozyme Pharma
Apr 8, 2025
Reiterates: Buy
Price Target: $15
Current: $0.91
Upside: +1,555.81%
Rhythm Pharmaceuticals
Apr 8, 2025
Reiterates: Buy
Price Target: $66
Current: $60.23
Upside: +9.58%
Cidara Therapeutics
Mar 7, 2025
Reiterates: Buy
Price Target: $35
Current: $17.47
Upside: +100.34%
Lexicon Pharmaceuticals
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.49
Upside: -
Mar 4, 2025
Reiterates: Buy
Price Target: $16
Current: $1.42
Upside: +1,026.76%
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.31
Upside: +663.36%
Feb 27, 2025
Reiterates: Buy
Price Target: $19
Current: $5.72
Upside: +232.17%
Feb 12, 2025
Reiterates: Hold
Price Target: n/a
Current: $105.25
Upside: -
Feb 11, 2025
Reiterates: Hold
Price Target: n/a
Current: $482.30
Upside: -
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $26.67
Upside: -
Nov 6, 2024
Maintains: Buy
Price Target: $85 → $60
Current: $19.61
Upside: +205.97%
Jun 13, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.90
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $14.96
Upside: +147.33%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $8.53
Upside: +111.02%